SEARCH:   Advanced

Blood, 15 October 2005, Vol. 106, No. 8, pp. 2912-2919. Prepublished online as a Blood First Edition Paper on June 30, 2005; DOI 10.1182/blood-2005-05-2004. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-05-2004v1 106/8/2912    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sorror, M. L. Articles by Storer, B. Search for Related Content PubMed PubMed Citation Articles by Sorror, M. L. Articles by Storer, B. Related Collections Transplantation Free Research Articles Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT Mohamed L. Sorror, Michael B. Maris, Rainer Storb, Frederic Baron, Brenda M. Sandmaier, David G. Maloney, and Barry Storer From the Fred Hutchinson Cancer Research Center, Seattle, WA; and the University of Washington, Seattle, WA. We previously reported that the Charlson Comorbidity Index (CCI) was useful for predicting outcomes in patients undergoing allogeneic hematopoietic cell transplantation (HCT). However, the sample size of patients with scores of 1 or more, captured by the CCI, did not exceed 35%. Further, some comorbidities were rarely found among patients who underwent HCT. Therefore, the current study was designed to (1) better define previously identified comorbidities using pretransplant laboratory data, (2) investigate additional HCT-related comorbidities, and (3) establish comorbidity scores that were suited for HCT. Data were collected from 1055 patients, and then randomly divided into training and validation sets. Weights were assigned to individual comorbidities according to their prognostic significance in Cox proportional hazard models. The new index was then validated. The new index proved to be more sensitive than the CCI since it captured 62% of patients with scores more than 0 compared with 12%, respectively. Further, the new index showed better survival prediction than the CCI (likelihood ratio of 23.7 versus 7.1 and c statistics of 0.661 versus 0.561, respectively, P < .001). In conclusion, the new simple index provided valid and reliable scoring of pretransplant comorbidities that predicted nonrelapse mortality and survival. This index will be useful for clinical trials and patient counseling before HCT. (Blood. 2005;106: 2912-2919) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: HCT outcomes: a new tool? Roy B. Jones Blood 2005 106: 2602-2603. [Full Text] [PDF] This article has been cited by other articles: J. Koreth, R. Schlenk, K. J. Kopecky, S. Honda, J. Sierra, B. J. Djulbegovic, M. Wadleigh, D. J. DeAngelo, R. M. Stone, H. Sakamaki, et al. Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: Systematic Review and Meta-analysis of Prospective Clinical Trials JAMA, June 10, 2009; 301(22): 2349 - 2361. [Abstract] [Full Text] [PDF] A. Dodero, C. Carniti, A. Raganato, A. Vendramin, L. Farina, F. Spina, C. Carlo-Stella, S. Di Terlizzi, M. Milanesi, P. Longoni, et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery Blood, May 7, 2009; 113(19): 4771 - 4779. [Abstract] [Full Text] [PDF] M. G. D. Porta and L. Malcovati Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome Haematologica, May 1, 2009; 94(5): 602 - 606. [Full Text] [PDF] E. Zipperer, D. Pelz, K. Nachtkamp, A. Kuendgen, C. Strupp, N. Gattermann, R. Haas, and U. Germing The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome Haematologica, May 1, 2009; 94(5): 729 - 732. [Abstract] [Full Text] [PDF] M. Rotta, B. E. Storer, F. Sahebi, J. A. Shizuru, B. Bruno, T. Lange, E. D. Agura, P. A. McSweeney, M. A. Pulsipher, P. Hari, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting Blood, April 2, 2009; 113(14): 3383 - 3391. [Abstract] [Full Text] [PDF] V. Bachanova, M. R. Verneris, T. DeFor, C. G. Brunstein, and D. J. Weisdorf Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation Blood, March 26, 2009; 113(13): 2902 - 2905. [Abstract] [Full Text] [PDF] H. D. Klepin and L. Balducci Acute Myelogenous Leukemia in Older Adults Oncologist, March 1, 2009; 14(3): 222 - 232. [Abstract] [Full Text] [PDF] J. J. Cornelissen, B. van der Holt, G. E. G. Verhoef, M. B. van 't Veer, M. H. J. van Oers, H. C. Schouten, G. Ossenkoppele, P. Sonneveld, J. Maertens, M. van Marwijk Kooy, et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison Blood, February 5, 2009; 113(6): 1375 - 1382. [Abstract] [Full Text] [PDF] E. Jantunen, C. Canals, A. Rambaldi, G. Ossenkoppele, B. Allione, D. Blaise, E. Conde, H. Tilly, G. Cook, F. Clark, et al. Autologous stem cell transplantation in elderly patients (>=60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry Haematologica, December 1, 2008; 93(12): 1837 - 1842. [Abstract] [Full Text] [PDF] J.-V. Malfuson, A. Etienne, P. Turlure, T. de Revel, X. Thomas, N. Contentin, C. Terre, S. Rigaudeau, D. Bordessoule, N. Vey, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia Haematologica, December 1, 2008; 93(12): 1806 - 1813. [Abstract] [Full Text] [PDF] U. Popat, R. Saliba, L. de Padua Silva, B. S Andersson, A. M Alousi, P. Anderlini, M. de Lima, G.-J. Okoroji, C. M Hosing, R. B Jones, et al. Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 799 - 799. [Abstract] [Full Text] C. Hosing, R. M. Saliba, G.-J. Okoroji, U. Popat, D. Couriel, T. Ali, L. De Padua Silva, P. Kebriaei, A. Alousi, M. De Lima, et al. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age Ann. Onc., June 1, 2008; 19(6): 1166 - 1171. [Abstract] [Full Text] [PDF] A. R. Rezvani, B. Storer, M. Maris, M. L. Sorror, E. Agura, R. T. Maziarz, J. C. Wade, T. Chauncey, S. J. Forman, T. Lange, et al. Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Relapsed, Refractory, and Transformed Indolent Non-Hodgkin's Lymphoma J. Clin. Oncol., January 10, 2008; 26(2): 211 - 217. [Abstract] [Full Text] [PDF] M. R. Baer, H. D. Klepin, and A. S. Artz Acute Leukemia in Older Adults: Are We Treating Too Much or Too Little? ASCO Educational Book, January 1, 2008; 2008(1): 216 - 223. [Abstract] [Full Text] [PDF] M. L. Sorror, B. E. Storer, D. G. Maloney, B. M. Sandmaier, P. J. Martin, and R. Storb Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia Blood, January 1, 2008; 111(1): 446 - 452. [Abstract] [Full Text] [PDF] M. L. Sorror, S. Giralt, B. M. Sandmaier, M. De Lima, M. Shahjahan, D. G. Maloney, H. J. Deeg, F. R. Appelbaum, B. Storer, and R. Storb Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences Blood, December 15, 2007; 110(13): 4606 - 4613. [Abstract] [Full Text] [PDF] C. G. Brunstein, J. N. Barker, D. J. Weisdorf, T. E. DeFor, J. S. Miller, B. R. Blazar, P. B. McGlave, and J. E. Wagner Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease Blood, October 15, 2007; 110(8): 3064 - 3070. [Abstract] [Full Text] [PDF] M. L. Sorror, B. M. Sandmaier, B. E. Storer, M. B. Maris, F. Baron, D. G. Maloney, B. L. Scott, H. J. Deeg, F. R. Appelbaum, and R. Storb Comorbidity and Disease Status Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation J. Clin. Oncol., September 20, 2007; 25(27): 4246 - 4254. [Abstract] [Full Text] [PDF] D. Blaise, N. Vey, C. Faucher, and M. Mohty Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia Haematologica, April 1, 2007; 92(4): 533 - 541. [Abstract] [Full Text] [PDF] F. Giles, D. Rizzieri, J. Karp, N. Vey, F. Ravandi, S. Faderl, K. Dad Khan, G. Verhoef, P. Wijermans, A. Advani, et al. Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia J. Clin. Oncol., January 1, 2007; 25(1): 25 - 31. [Abstract] [Full Text] [PDF] J. H. Antin Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2 Hematology, January 1, 2007; 2007(1): 47 - 54. [Abstract] [Full Text] [PDF] M. Sorror, B. M. Sandmaier, B. Storer, M. B. Maris, D. G. Maloney, and R. Storb Impacts of Comorbidities on Outcomes of Patients (pts) Diagnosed with B-Cell Malignancies and Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative (NM) vs Myeloablative (M) Conditioning. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 550 - 550. [Abstract] [Full Text] [PDF] F. Giles, G. Borthakur, F. Ravandi, S. Faderl, S. Verstovsek, S. Pierce, E. Jabbour, J. Cortes, and H. Kantarjian Comorbidity Scoring Using the Hematopoetic Cell Transplantation Comorbidity Index (HCTCI) Is Predictive of Early Death Rate and Event Free Survival (EFS) in Patients over 60 Years of Age Receiving Induction Therapy for Acute Myeloid Leukemia (AML). Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 1975 - 1975. [Abstract] [PDF] G. Abdalla, K. A. Guthrie, M. L. Sorror, and M. Linenberger Apheresis Safety and Product Yield among Elderly Donors for Allogeneic Sibling Hematopoietic Cell Transplantation (HCT). Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 5223 - 5223. [Abstract] [PDF] F. Baron, R. Storb, B. E. Storer, M. B. Maris, D. Niederwieser, J. A. Shizuru, T. R. Chauncey, B. Bruno, S. J. Forman, P. A. McSweeney, et al. Factors Associated With Outcomes in Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning After Failed Myeloablative Hematopoietic Cell Transplantation J. Clin. Oncol., September 1, 2006; 24(25): 4150 - 4157. [Abstract] [Full Text] [PDF] T. Parimon, D. H. Au, P. J. Martin, and J. W. Chien A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med, March 21, 2006; 144(6): 407 - 414. [Abstract] [Full Text] [PDF] B. L. Scott and B. M. Sandmaier Outcomes with Myeloid Malignancies Hematology, January 1, 2006; 2006(1): 381 - 389. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020